Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
PFE
$24.58
Pfizer
$.35
1.44%
PFE
Earnings Whisper ®
N/A
3rd Quarter September 2025
Consensus: $0.81
Revenue: $17.32 Bil
Tuesday
Nov 4
6:45 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Guidance announcement made Tuesday, August 5, 2025
Latest EPS
Tuesday, August 5, 2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
What do you expect when PFE reports earnings?
Beat
Meet
Miss
Where is PFE's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$25.19
$24.90
$24.74
$24.45
Support
$24.29
$24.00
$23.84
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Peers
Vertex Pharmaceuticals
BioMarin Pharmaceutical
Bristol Myers Squibb
Eli Lilly
Regeneron Pharmaceuticals
Merck & Co.
Johnson & Johnson
ARRAY Technologies
Ultragenyx Pharmaceutical
Insmed
Expectations
›
Pfizer